Menu
Curie Logo
Donate
  • Home

Clinical trials - page 6

Essais cliniques
Search for a clinical trial
Filter

192 result(s)

  • Digestive cancers
    Paris, Saint-Cloud
    ProActIF-01
    ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers

    TIMOTHEE MARCHAL

  • Saint-Cloud
    QPL-MDS
    Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

    SANDRA MALAK

  • Lung cancer
    Paris
    R2810-ONC-2268
    A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075

    NICOLAS GIRARD

  • Myélome
    Saint-Cloud
    R5458-ONC-2245
    An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-;BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab,;Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory;Multiple Myeloma (LINKER-MM3).

    Cyrine ELLOUZ

  • Thymic tumors
    Paris
    RADIO-RYTHMIC-01 (IC 2020-09)
    Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma

    NICOLAS GIRARD

  • Cancers gynécologiques
    Paris
    RAINBO
    Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials · p53abn - RED.

    AUDREY BELLESOEUR

  • Saint-Cloud
    REGOMUNE
    A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

    SEGOLENE HESCOT

  • Childhood and adolescent cancers
    Paris
    RETINO-2018 (IC 2019-05)
    Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018

    LIVIA LUMBROSO-LE ROUIC

  • Lung cancer
    Paris
    RMC-LUNG-101
    Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors

    PAULINE DU RUSQUEC

  • Cancers gynécologiques
    Paris
    ROCSAN
    A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

    AUDREY BELLESOEUR

  • Saint-Cloud
    RTEP7 (IFCT-1402)
    Randomized Phase II-III Study of Personalized Radiotherapy Dose Redistribution in Patients With Inoperable Stage III Non-small Cell Lung Cancer and a Persistent FDG Uptake at 42 Grays During Concomitant Radio-chemotherapy.

    MARIE ANGE MASSIANI

  • Saint-Cloud
    SAFIR ABC10
    Clinical trial of precision medicine in patients with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer).

  • Eye tumors / Uveal melanoma
    Paris
    SALOME / IC 2019-13
    Follow-up of patients with uveal melanoma adapted to the risk of relapse.

    SOPHIE PIPERNO-NEUMANN

  • Cancer de l'ovaire
    Paris, Saint-Cloud
    SALVOVAR
    A pragmatic randomized phase III trial to assess the utility of adjusting;chemotherapy dose & dosing schedule with the SALVage weekly dose-dense;regimen in patients with poor prognostic OVARian cancers based on the tumor;unfavorable primary chemosensitivity and incomplete debulking surgery.

    CLEMENT BONNET

  • Paris, Saint-Cloud
    SCANDARE (IC 2016-03)
    Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.

    CHRISTOPHE LE TOURNEAU

  • Saint-Cloud
    SERENA-4
    SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    SIOP EPENDYMOMA II
    An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma

    FRANCOIS DOZ

  • Breast cancer
    Paris, Saint-Cloud
    SKYLINE
    Tiragolumab, atezolizumab and chemotherapy in triple negative breast cancer:;A phase II trial.

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    START
    A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine

    FLORENCE LEREBOURS

  • Saint-Cloud
    STERIMGLI
    A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI).

  • Sarcomas
    Paris
    STRASS 2 - ETUDE 1809-STBSG
    A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2)

    SYLVIE BONVALOT

  • Saint-Cloud
    SUMMIT- PUMA-NER-0502
    An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.

    FRANCOIS-CLEMENT BIDARD

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    SURVEILLE HPV
    National, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.

    JOEY MARTIN

  • Childhood and adolescent cancers
    Paris
    Selupass
    Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study

    ISABELLE AERTS GAJDOS

  • Sarcomas
    Paris
    TANGENT (SNX-301-020)
    A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

    SOPHIE PIPERNO-NEUMANN

  • Lung cancer
    Paris
    TAS6417-201
    An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    TAS6417-301
    Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.

    NICOLAS GIRARD

  • Saint-Cloud
    TEDOPaM Prodige 63
    A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study).

  • Prostate cancer
    Paris, Saint-Cloud
    TEMPOS (GETUG P14)
    Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy

    GILLES CREHANGE

  • ENT/Head and Neck Cancers
    Paris
    TG4050.02
    A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence

    CHRISTOPHE LE TOURNEAU

<
1 ...67
>